CD44 and breast carcinoma: CD44, a glycoprotein on the surface of the cell, participates in immune recognition, cell‐to‐cell and cell‐to‐matrix interactions, cell migration, and other processes.[74] HA is a promising ligand for targeting CD44‐overexpressing breast cancer cells, such as MDA‐MB‐231 cells (Figure 5b).